Aktienanalyse zu Bio-Rad Laboratories, Inc. (BIO.B)BIO.BBio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories. It operates in the Healthcare sector.

Bio-Rad Laboratories Inc is a good buy right now due to its strong recent performance, with a 20-day change of +18.01% and a current price of 365.08, which is significantly above its 200-day simple moving average of 299.542. Additionally, the stock has a high RSI of 99.938, indicating strong momentum. However, the main risk is the negative earnings per share (EPS) of -19.55 reported in Q1 2026, which could impact investor sentiment.